Literature DB >> 7531679

Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.

I Barista1, G Tekuzman, D Firat, E Baltali, E Kansu, A Kars, Y Ozisik, S Ruacan, B Uzunalimoğlu, E Karaağaoğlu.   

Abstract

In this retrospective study, 470 patients with non-Hodgkin's lymphoma (NHL) who had been followed in the Hacettepe University Medical Oncology Department between 1973 and 1990, were evaluated to establish their epidemiologic, clinical and therapeutic characteristics. Out of 470 patients, 302 (62.2%) were male and 168 (37.8%) were female. The ages ranged from 16 to 85, with a median of 44 years. Constitutional symptoms were present in 46.4% of the patients. According to the Working Formulation, low, intermediate, and high-grade lymphomas comprised 33.4%, 54.9%, and 12.7%, respectively. The most common extranodal presentation was gastrointestinal. The chemotherapy regimens most commonly used were CVP (cyclophosphamide, vincristine, prednisone), BCNOP (bleomycin, cyclophosphamide, mitoxantrone, vincristine, prednisone), CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and CHOP-Bleo (cyclophosphamide, doxorubicin, vincristine, prednisone, bleomycin). The response rates and the survival figures attained with these regimens were not statistically significantly different (P > 0.05). In the Cox multivariate model, pathologic grade, leukopenia, responsiveness to chemotherapy, bone marrow involvement and age were the important factors influencing the disease-free survival, while responsiveness to chemotherapy, age, presence of constitutional symptoms, pathologic grade, extranodal presentation and stage were the important factors influencing the overall survival. The distribution of NHL according to grade and stage was similar to that in western societies, while constitutional symptoms and lymphomas of the small intestine including immunoproliferative small intestinal disease were more common in Turkey.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531679      PMCID: PMC5919392          DOI: 10.1111/j.1349-7006.1994.tb02930.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  37 in total

1.  Large-cell lymphomas: clinical and prognostic features.

Authors:  R S Stein; J P Greer; J M Flexner; J D Hainsworth; R D Collins; W R Macon; J B Cousar
Journal:  J Clin Oncol       Date:  1990-08       Impact factor: 44.544

2.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

3.  Non-Hodgkin's lymphomas in Turkey.

Authors:  S C Sarpel; S Paydas; I Tuncer; S Varinli; M Koksal; T Akoglu
Journal:  Cancer       Date:  1988-10-15       Impact factor: 6.860

4.  Survival following combination chemotherapy in advanced high grade non-Hodgkin's lymphomas: relation to proliferative activity of the lymphoma cells.

Authors:  L Brandt; H Olsson
Journal:  Eur J Haematol       Date:  1987-05       Impact factor: 2.997

5.  Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma.

Authors:  L Endrizzi; M V Fiorentino; L Salvagno; R Segati; G L Pappagallo; V Fosser
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10

6.  Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation.

Authors:  J M Vose; J O Armitage; P J Bierman; D D Weisenburger; M Hutchins; M D Dowling; D F Moravec; S Sorensen; J Okerbloom; G Bascom
Journal:  Am J Med       Date:  1989-09       Impact factor: 4.965

7.  Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen.

Authors:  B Coiffier; E Lepage
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

8.  Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data.

Authors:  W S Velasquez; S Jagannath; S L Tucker; L M Fuller; L B North; J R Redman; F Swan; F B Hagemeister; P McLaughlin; F Cabanillas
Journal:  Blood       Date:  1989-08-01       Impact factor: 22.113

9.  Primary gastrointestinal lymphoma in Kuwait. An 11-yr retrospective analysis of 108 cases.

Authors:  Y T Omar; B Al-Nakib; G S Jacob; S M Ali; L Temmim; S Radhakrishnan; M S Fayaz
Journal:  Eur J Cancer Clin Oncol       Date:  1985-05

10.  Non-Hodgkin's lymphomas in Jordanians: a histopathological study of 231 cases.

Authors:  M S Tarawneh
Journal:  Hematol Oncol       Date:  1986 Jan-Mar       Impact factor: 5.271

View more
  2 in total

1.  [Initial diagnosis of malignant lymphomas with manifestations in the mouth cavity and adjacent tissues].

Authors:  S Colbow; B Langanke; U Teuber
Journal:  Mund Kiefer Gesichtschir       Date:  1997-02

2.  The clinicopathologic features and response to treatment of patients with Nonhodgkin Lymphoma: A single-center experiment in Turkey.

Authors:  Rahsan Yildirim; Gulden Sincan
Journal:  Pak J Med Sci       Date:  2019 Jan-Feb       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.